These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22124178)

  • 1. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.
    Pang T; Benicky J; Wang J; Orecna M; Sanchez-Lemus E; Saavedra JM
    J Hypertens; 2012 Jan; 30(1):87-96. PubMed ID: 22124178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes.
    Larrayoz IM; Pang T; Benicky J; Pavel J; Sánchez-Lemus E; Saavedra JM
    J Hypertens; 2009 Dec; 27(12):2365-76. PubMed ID: 19730394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
    Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
    Bähr IN; Tretter P; Krüger J; Stark RG; Schimkus J; Unger T; Kappert K; Scholze J; Parhofer KG; Kintscher U
    Hypertension; 2011 Oct; 58(4):725-32. PubMed ID: 21876071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
    Song KH; Park JH; Jo I; Park JY; Seo J; Kim SA; Cho DH
    Vascul Pharmacol; 2016 Mar; 78():43-52. PubMed ID: 26455386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
    Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways.
    Pang T; Wang J; Benicky J; Sánchez-Lemus E; Saavedra JM
    J Neuroinflammation; 2012 May; 9():102. PubMed ID: 22642771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation.
    Elkahloun AG; Rodriguez Y; Alaiyed S; Wenzel E; Saavedra JM
    Mol Neurobiol; 2019 May; 56(5):3193-3210. PubMed ID: 30105672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
    Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
    Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
    Clemenz M; Frost N; Schupp M; Caron S; Foryst-Ludwig A; Böhm C; Hartge M; Gust R; Staels B; Unger T; Kintscher U
    Diabetes; 2008 May; 57(5):1405-13. PubMed ID: 18184928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
    Schupp M; Janke J; Clasen R; Unger T; Kintscher U
    Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
    Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
    Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.